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These guidelines for prophylactic anticoagulation reflect 
current best practice. However, every patient should still be 
assessed on merit, with individualisation of therapy where 
indicated. Drug recommendations are based on Medicines 
Control Council registration at the time of publication, unless 
otherwise indicated.
1. Medical patients
1.1 Background
In the absence of anticoagulation, the risk of deep vein 
thrombosis (DVT) in medically ill patients is comparable to 
that observed in moderate-risk surgical patients: 10 - 20%. 
Although the clinical significance of asymptomatic distal DVT 
is debatable, pulmonary embolism (PE) is the most common 
preventable cause of death in hospital patients, accounting for 
10% of all hospital deaths. Three-quarters of these deaths occur 
in medically ill patients. The efficacy of heparins in preventing 
venous thromboembolism (VTE) in medically ill patients is 
now well established. However, their use is associated with 
an increased risk of major bleeding episodes, and this factor 
should be balanced against the thrombotic risk.
1.2 Risk assessment
Risk assessment is essential and treatment needs to be 
individualised. Refer to Appendix 1 for further information.
1.3 Recommendations
1.3.1 Prophylaxis in medically ill patients
The recommended prophylactic doses for low-molecular-
weight heparin (LMWH) and unfractionated heparin are as 
follows:
•    enoxaparin 40 mg (4 000 anti-Xa units) sc (subcutaneous) 
daily
or
•    unfractionated heparin (UFH) 5 000 units sc tds (3 times per 
day).
Evidence-based data show LMWH to be superior to 
unfractionated heparin.
LMWH should be given to all bedridden medically ill patients 
who have:
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Background. Pharmacological prophylactic anticoagulation in 
many countries, including South Africa, is under-prescribed, 
which unfortunately results in unacceptable morbidity and 
mortality in a substantial number of patients.
Method. The Southern African Society of Thrombosis and 
Haemostasis reviewed the available literature as well as 
guidelines from other societies. Specialties represented on 
the committees included anaesthetics, cardiology, clinical 
haematology, critical care, gynaecology, haematopathology, 
internal medicine, neurology, orthopaedic surgery, 
pulmonology and vascular surgery. A draft document was 
produced, which was revised by consensus agreement. 
To avoid local bias, the guidelines were adjudicated by 
recognised independent international external experts.
Results and conclusion. A concise, practical guideline for 
thrombo-prophylaxis and treatment in medical and 
surgical patients has been produced for South African 
conditions. These guidelines will hopefully lead to improved 
anticoagulation practice in this country, which we believe will 
directly benefit patient outcomes.
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Table I. Prevalence of DVT in various patient populations
Patient population   Prevalence of DVT
Internal medicine   10 - 20%
General surgery   15 - 40%
Major gynaecological surgery  15 - 40%
Major urological surgery  15 - 40%
Neurosurgery   15 - 40%
Stroke    15 - 40%
Hip and knee replacement surgery 40 - 60%
Hip fractures   40 - 60%
Polytrauma   40 - 80%
Spinal cord injury   60 - 80%
Critical care    10 - 80%
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•    conditions associated with a high risk of thrombosis (see 
Appendix 1)
or
•    other medical conditions (such as acute infections or acute 
rheumatic disease) with at least one associated risk factor.
Note: Prophylaxis is not required for patients who are mobile.
In patients at high risk of bleeding, the use of mechanical 
prophylaxis such as graduated compression stockings (GCS) or 
intermittent pneumatic compression (IPC) devices should be 
considered as an alternative if the thrombotic risk is high.
1.4 Monitoring – see General recommendations
2. Surgical patients
2.1 Background
Refer to the comments above (under 1.1) regarding background 
and risk assessment. Furthermore, VTE is an important cause 
of morbidity and mortality in surgical patients. However, the 
relative risk of developing VTE varies among patients, and 
some measure of risk assessment is required for appropriate 
selection of prophylaxis. The following guidelines attempt 
to simplify risk assessment models, which are often too 
complicated for routine use.
Both patient-related and procedure-related risk factors 
should be considered when assessing an individual’s risk of 
developing VTE.
2.1.1 Patient-related risk factors for VTE
•   age >60
•   previous history of VTE
•   immobility
•   underlying malignancies
•   pregnancy
•   oestrogen replacement therapy
•   obesity
•   underlying hereditary thrombophilic state
•   underlying inflammatory bowel disease.
2.1.2 Procedure-related risk factors
•   duration of procedure
•    degree of tissue damage (orthopaedic and trauma surgery 
carry the greatest risk)
•   degree of immobility following surgery
•    nature of surgical procedure (e.g. lower limb orthopaedic 
surgery, neurosurgery, etc.).
2.2 Recommendations
2.2.1 Prophylaxis in surgical patients
2.2.1.1. Patients undergoing low-risk procedures (minor 
surgery) with no patient-related risk factors:
•   no specific prophylaxis is required
•   early mobilisation is recommended.
2.2.1.2. Patients undergoing higher-risk procedures (major 
surgery) with no patient-related risk factors OR undergoing 
low-risk procedures with additional patient-related risk 
factors:
Enoxaparin 40 mg (4 000 anti-Xa units) sc daily
or
Dalteparin 0.2 ml (2 500 anti-Xa units) sc daily. 
or
Nadroparin.
Abdominal surgery: 0.3 ml (2 850 anti-Xa units) sc 2 hours pre-
operatively and 8 hours after surgery, followed by 0.3 ml daily 
for 7 days.
Knee and hip replacement surgery: Weight-adjusted dose of 
38 anti-Xa units/kg sc 12 hours preoperatively and repeated 
12 hours after surgery and daily on days 1 - 3 with 57 anti-Xa 
units/kg sc from day 4 for a minimum of 10 days.
Prophylaxis should generally be given 12 hours before 
surgery and once-daily post-operatively (see Timing 
of prophylaxis (2.2.2) below). Intermittent pneumatic 
compression (IPC) devices may be acceptable alternatives, 
particularly if minor bleeding is likely to be harmful or if other 
factors suggest an increased bleeding risk. Therefore, if feasible 
and practical, IPC devices should be utilised.
2.2.1.3. Patients undergoing higher-risk procedures (major 
surgery) with additional patient-related risk factors OR 
undergoing very high-risk procedures (orthopaedic or trauma 
surgery):
Enoxaparin 40 mg (4 000 anti-Xa units) sc daily
or
Dalteparin 0.4 ml (5 000 anti-Xa units) sc daily
or
Nadroparin.
Abdominal surgery: 0.3 ml (2 850 anti-Xa units) sc 2 hours pre-
operatively and 8 hours after surgery, followed by 0.3 ml daily 
for 7 days.
Knee and hip replacement surgery: weight-adjusted dose of 38 
anti-Xa units/kg sc 12 hours pre-operatively and repeated 12 
hours after surgery and daily on days 1 - 3, with 57 anti-Xa 
units/kg sc from day 4 for a minimum of 10 days.
Fondaparinux 2.5 mg sc daily (NB: only registered for 
prophylaxis in total hip and knee replacement surgery and 
arthroplasty, and only to be administered after surgery).
See paragraphs below on timing and duration of 
prophylaxis. Consideration should be given in this group of 
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patients to using additional mechanical devices such as IPC 
devices.
2.2.2 Timing of prophylaxis
This is an extremely controversial matter! Data are available 
confirming the benefits of prophylactic anticoagulation 
initiated pre-operatively that, although desirable, is not always 
possible. However, it should be given postoperatively within 
6 - 12 hours (6 hours if bleeding risk is minor and 12 hours if 
bleeding risk is major) i.e. not before 6 hours postoperatively 
and not after 12 hours postoperatively, provided that no 
active bleeding is present. For major hip and knee surgery, a 
postoperative initiation time of 12 hours appears to be optimal.
Adjustment of the dose with renal failure is mandatory 
(refer to package inserts of individual drugs). The first 
dose of fondaparinux should always be given 6 - 8 hours 
postoperatively. In patients at high risk of bleeding or 
undergoing regional anaesthesia (see separate guidelines), 
anticoagulation should always only be initiated 12 hours 
postoperatively. Not all experts agree that pre-operative dosing 
is essential.
2.2.3 Duration of prophylaxis
•   General recommendations:
•   major cancer surgery: 5 weeks
•   hip replacement surgery: 5 weeks
•   knee replacement surgery: 2 weeks
•    LMWH prophylaxis should be continued until the patient is 
fully mobile.
•    For major surgery in patients with additional risk factors or 
very high-risk procedures (e.g. major orthopaedic surgery), 
at least 7 - 10 days’ prophylaxis is indicated.
•    Extended out-of-hospital prophylaxis (up to 1 month) with 
LMWH or warfarin started immediately postoperatively 
and adjusted to maintain an international normalised ratio 
(INR) of 2 - 3 has been shown to provide additional benefit.
For monitoring of LMWH, see General recommendations.
2.2.4 Special circumstances
2.2.4.1 Recommendations with reference to centroneuro-axial 
blockade (spinal and epidural anaesthesia) in the setting of 
prophylactic doses
•    Catheter should not be placed or removed within 12 
hours after a dose of LMWH.
•    LMWH should not be commenced less than 2 hours after 
insertion or removal of a neuro-axial catheter.
•    LMWH should be delayed at least 24 hours if there is 
blood in the needle or neuro-axial catheter during needle 
insertion.
•    Neurological monitoring is mandatory for a minimum 
of 12 hours and ideally for 72 hours after neuro-axial 
blockade in association with anticoagulation.
•    Extreme caution should be exercised in patients on other 
haemostatically active agents such as aspirin and non-
steroidal anti-inflammatory agents.
•    Currently, only limited data are available on the 
utilisation of fondaparinux in this setting. The committee 
is therefore unable to make definitive recommendations 
for this drug. Because of the drug’s long half-life, catheter 
removal should not take place less than 36 hours after 
cessation of fondaparinux.
2.2.4.2 Recommendations with reference to prophylaxis in 
pregnancy
There are no drugs registered for these indications in 
pregnancy; these are therefore off-label recommendations. (All 
other recommendations in these guidelines are as per registered 
indications/‘on-label’.)
•    In healthy pregnant women undergoing a procedure 
(e.g. caesarean section) under centroneuro-axial blockade 
or general anaesthesia with no specific risk factors, it is 
recommended that non-pharmacological methods and 
early mobilisation be practised.
•    In pregnant women with risk factors for thrombosis (e.g. 
obesity), LMWH prophylaxis is safe for the mother and 
fetus and should be commenced within 6 hours after 
caesarean section/normal vaginal delivery as described 
under Prophylaxis in surgical patients (2.2.1) above. 
However, if neuro-axial anaesthesia has been used, 
initiation of prophylaxis should be delayed for 12 hours.
2.2.5 General recommendations
2.2.5.1 Monitoring of patients on LMWH
•    The patient’s platelet count should be checked on initiation 
of LMWH, after 5 days, and regularly thereafter while on 
therapy.
•    Anticoagulant activity is measured using an anti-Xa activity 
assay.
•    Anti-Xa measurement is only indicated in pregnancy, renal 
failure or excessively obese patients for whom large doses 
are required.
•    The anti-Xa assay must be calibrated for each LMWH tested.
•    The anti-Xa assay for enoxaparin and nadroparin is 
currently available from the Johannesburg Hospital 
Haematology Laboratory (011 488-3068 or 011 489-8552), as 
well as from most private laboratories.
•    5 ml citrated blood taken 3 hours post LMWH dose is 
required for the assay.
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•   Target levels
•    Prophylaxis target is 0.3 - 0.5 anti-Xa units/ml of blood.
•    Therapeutic target is 0.6 - 1.0 anti-Xa units/ml of blood.
•    Target values for therapeutic anticoagulation in pregnant 
patients with an artificial cardiac valve is 1 - 1.2 anti-Xa 
units/ml of blood.
2.2.5.2 Management of bleeding patients
•   Do not use prophylaxis if there is severe bleeding.
•    Discontinue LMWH as well as any other haemostatically 
active agents that may contribute to haemorrhage.
•    Supportive care includes transfusion of blood products.
•   Measurement of anti-Xa levels may be indicated.
•    Protamine sulphate is effective in neutralising the 
antithrombin activity of LMWH but has limited effect on the 
anti-Xa activity. Consider protamine sulphate if bleeding is 
severe.
•    A dose of 1 mg protamine sulphate reverses the effect 
of 100 anti-Xa units of LMWH (1 mg enoxaparin is 
equivalent to ∼100 anti-Xa units). To reverse the effect of 
40 mg enoxaparin, 40 mg protamine sulphate is needed.
•    If the patient continues to bleed, a repeat dose of 0.5 mg 
protamine sulphate per 100 anti-Xa units of enoxaparin is 
indicated, and can be repeated to a maximum of 3 doses.
3. Guidelines for treatment of venous 
thrombo-embolism (VTE)
3.1 Initiation of anticoagulation
LMWH offers definite advantages over UFH because not 
only is the dosing convenient but there is also no need to 
monitor patients, which allows for the possibility of outpatient 
management for certain patients; it may also result in a reduced 
risk of recurrence. The guidelines below pertain to the use of 
LMWH.
Enoxaparin 1 mg/kg sc twice daily
or
Nadroparin weight adjusted 0.1 ml/10 kg sc twice daily 
(according to manufacturer’s guidelines)
or
Dalteparin 100 anti-Xa units/kg sc twice daily.
•   The above drugs should be given for at least 7 days.
•    Warfarin should be started at a dose of 5 mg po daily from 
day 2 of anticoagulation. The practice of giving a ‘loading 
dose’ has been discontinued.
•    The INR should be measured 2 - 3 days after starting 
warfarin and then daily, with dose adjustments to achieve a 
therapeutic range of 2 - 3 (for most indications).
•    LMWH must be given for at least 7 days, even if the INR 
has reached therapeutic level.
•    LMWH can be discontinued once the INR has been in the 
therapeutic range for 2 consecutive days.
•    For massive thrombosis or pulmonary embolism, LMWH 
should be given for 7 - 10 days.
•    For massive pulmonary embolism, thrombolytic therapy is 
indicated in the presence of haemodynamic compromise e.g. 
r-TPA 100 mg IV over 2 hours.
3.2 Duration of oral anticoagulation
The duration needs to be individualised according to 
the patient’s thrombo-embolic risk level; only basic 
recommendations are given here.
•    Patients with reversible or time-limited risk factors should 
be treated for at least 3 months.
•    Patients with idiopathic DVT and all patients with PE 
should be treated for at least 6 months.
•    Patients with recurrent idiopathic VTE, or continuing risk 
factors, or who have had a life-threatening event, or have 
had a thrombosis in an unusual site, may benefit from 
longer duration anticoagulation, possibly lifelong in some 
patients.
•    Underlying antithrombin deficiency, antiphospholipid 
syndrome or malignancy carry the highest risk of relapse, 
and lifelong anticoagulation as secondary prophylaxis 
should be considered in these settings. The presence of 
multiple concurrent risk factors also significantly increases 
the risk of recurrence.
•    NB: The presence of heterozygous factor V Leiden is a 
weak independent risk factor for recurrence and is not an 
indication for long-term anticoagulation following a first 
event.
•    Spontaneous superficial thrombophlebitis: Current data 
suggest intermediate dose LMWH for 1 month.
3.3 Venacaval filters
Venacaval filters are indicated in the following circumstances:
•   recurrent VTE despite adequate anticoagulation
•   contraindications to anticoagulation, such as head injury
•   inability to achieve optimal anticoagulation.
3.4 Catheter-directed thrombolysis
This may be indicated in centres with the necessary expertise 
for young healthy patients with a large clot burden, especially 
in ilio-femoral thrombosis.
3.5 Thrombophilia screening
The presence of an underlying hereditary thrombophilic state 
does not alter initial management, and thrombophilia screening 
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should be delayed until 2 weeks after discontinuation of 
therapy because the results are altered by the acute event and 
by anticoagulant therapy.
3.6 Outpatient management
Management of VTE in the outpatient setting is safe and cost-
effective provided that:
•    the patient is able to understand and administer therapy 
himself/herself
•    the patient is able to attend regular follow-up and has rapid 
access to hospital care should it be required
•    no complicating factors (e.g. increased bleeding risk) are 
present.
3.7 Management of non-therapeutic INRs
This should be individualised according to bleeding risk. 
Below are general guidelines:
•   INR <5 no significant bleeding:
•   omit warfarin
•   re-start lower dose once INR is in the therapeutic range.
•   INR >5<10 no significant bleeding:
•   omit warfarin
•   monitor INR daily until back in therapeutic range
•   restart warfarin at lower dose
•    consider low-dose oral vitamin K if INR remains 
prolonged.
•   INR >10 no significant bleeding:
•   stop warfarin
•   give vitamin K 2 mg po
•    monitor INR daily until in therapeutic range (repeat 
vitamin K as required)
•   restart warfarin at lower dose.
•   Patients with significant bleeding:
•   stop warfarin
•    give fresh frozen plasma (FFP) or bioplasma or 
prothrombin complex concentrate (if bleed is life-
threatening)
•   give vitamin K slowly intravenously.
Special precautions should be exercised when reversing 
anticoagulation in patients with prosthetic heart valves.
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Appendix 1
Risk assessment: VTE risk factors can be divided into 
predisposing factors (i.e. patient characteristics) and exposing 
factors (i.e. some medical conditions, nature of surgical 
intervention, etc.) (see tables).
VTE risk factors
Predisposing risk factor              Relative risk weighting
Thrombophilia                High
History of VTE                High
Malignancy                High
Drugs, e.g.                High
• tuberculosis treatment
• steroids
• thalidomide
HIV infection                High
Advanced age (>60 yrs =                Moderate
increased VTE risk)
Chronic cardiac insufficiency               Moderate
Obesity (BMI >30 kg/m2)               Moderate
Oestrogen therapy                Moderate
Pregnancy and the                 Minor
postpartum period
Nephrotic syndrome               Minor
Varicose veins                               Minor
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Subcategories of VTE risk in surgical and non-surgical patients
          Surgical patients         Medical patients 
Low VTE risk         • Surgery lasting <30 minutes        • Infection or acute inflammatory diseases
          • Injuries without or with only minor          without bed rest
             soft-tissue trauma         • Central venous catheters
          • No or only minor additional        • No, or only minor, additional
             predisposing risk factor            predisposing risk factors
Moderate VTE risk         • Surgical procedures of longer duration       • Acute cardiac insufficiency
          • Immobilisation of lower limb           (NYHA III/IV)
             with plaster cast         • Acute decompensated
          • Lower limb arthroscopic procedures          COPD without ventilation
          • No or only minor additional        • Infection or acute inflammatory
             predisposing risk factors           diseases with bed rest
                      • Malignancy
                      • No or only minor additional
                  predisposing risk factors
High VTE risk          • Major surgical procedures        • Stroke with paralysis
             for malignancy         • Acute decompensated COPD
          • Multiple trauma or severe trauma of          with ventilation
             the spine, vertebrae or lower limbs       • Sepsis
          • Major orthopaedic surgery e.g. hip or       • ICU patients
             knee replacement
          • Major surgical procedure of
             cardiothoracic and pelvic region
